Dolkar R, Paudwal G, Singh D, Behera C, Malik SB, Ali SM, Kaur H, Nargotra A, Shankar R, Singh SK, Gupta PN.

Mechanistic Approach into 1,2,3-triazoles-based

IIIM(S)-RS98 Mediated Apoptosis in Lung Cancer Cells.

AAPS J. 2025 Feb

3;27(1):35. doi: 10.1208/s12248-025-01018-9.

Aboti J, Parvez M, Zuhaid M, Sharma S, Basit R, Kour M, Sharma K, Singh SK, Chashoo G, Haneef J, Naveen M, Samim M, Giovanuzzi S, Supuran CT, Shafi S.

Synthesis of benzenesulfonamide tethered pyrazolyl stilbene derivatives: Their anti-proliferative and carbonic anhydrase inhibitory potentials.

Bioorg Chem. 2025 Jun 9;163:108662. doi: 10.1016/j.bioorg.2025.108662

Cham PS, Singh A, Jamwal A, Singh R, Anand R, Manhas D, Sharma S, Singh VP, Nandi U, Singh SK, Singh PP.

Discovery of Ring-Annulated Analogues of Cannabidiol as Potential Anticancer Agents: Synthesis and Biological Evaluation.

ACS Med Chem Lett. 2024 Oct 17;15(11):1832-1842. doi:10.1021/acsmedchemlett.4c00233.

Thapa S, Nalli Y, Singh A, Singh SK, Ali A.

Cells. Oxid Med Cell Longev. 2024 Feb 13;2024:3530499. doi:

10.1155/2024/3530499.

Chopra C, Yodun T, Singh H, Singh B, Singh SK, Goutam U.

Raloxifene, a SERM targets PD-L1: an in-silico study.

Am J Transl Res. 2023 Aug 15;15(8):5206-5215.

Kushwaha M, Qayum A, Sharma N, Abrol V, Choudhary P, Murtaza M, Singh SK, Vishwakarma RA, Goutam U, Jain SK, Jaglan S. Correction to “LC-PDA-MS/MS-Based

Dereplication Guided Isolation of a New Optical Isomer of 19,20-Epoxycytochalasin-N and Its Cytotoxic Activity”.

ACS Omega. 2023 Feb 6;8(7):7243. doi: 10.1021/acsomega.3c00349.

Khan A, Naaz F, Basit R, Das D, Bisht P, Shaikh M, Lone BA, Pokharel YR, Ahmed QN, Parveen S, Ali I, Singh SK, Chashoo G, Shafi

ACS Omega. 2022 Sep 1;7(36):32078-32100. doi:10.1021/acsomega.2c03325

Qayum A, Singh J, Kumar A, Shah SM, Srivastava S, Kushwaha M, Magotra A, Nandi U, Malik R, Shah BA, Singh SK

2-Pyridin-4-yl-methylene-beta-boswellic Acid-A Potential Candidate for Targeting O⁶-Methylguanine-DNA Methyltransferase Epi-transcriptional Reprogramming in KRAS G13D-Microsatellite Stable, G12V-Microsatellite Instable Mutant Colon Cancer.

ACS Pharmacol Transl

Sci. 2022 Apr 18;5(5):306-320. doi: 10.1021/acsptsci.1c00228.

Qayum A, Magotra A, Shah SM, Nandi U, Sharma PR, Shah BA, Singh SK.

Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells.

Heliyon. 2022 Mar 16;8(4):e09103.

doi: 10.1016/j.heliyon.2022.e09103.

Kushwaha M, Qayum A, Jain SK, Singh J, Srivastava AK, Srivastava S, Sharma N, Abrol V, Malik R, Singh SK, Vishwakarma RA, Jaglan S.

Tandem MS-Based Metabolite Profiling of 19,20-poxycytochalasin C Reveals the Importance of a Hydroxy Group at the C7 Position for Biological Activity.

ACS Omega. 2021 Jan 25;6(5):3717-3726

Rafia Basit, Ajeet Singh, Tenzen Yodun, Ghulam Mustafa, Ramajayan Pandian, Umed Singh, Parvinder Pal Singh, Gousia Chashoo, Shashank Kumar Singh

Synergistic Effects of IIIM-368 and Paclitaxel Combination Therapy: An Enhancement in the Lung Cancer Treatments

0087NF2024/IN

(Pending: 2024)

Pankaj Singh Cham, Ajeet Singh, Ashiya Jamwal, Rattandeep Singh, Shabu, Sonia Thapa, Priya Wazir, Utpal Nandi, Shashank Kumar Singh, Parvinder Pal Singh

(N-alkyldihydrol-2h-oxazinyl)-cannabidiol as anti-proliferative agent and process for preparation thereof

0178NF2022/IN

(Granted : 2022)

Ahmed Kamal, Yellamelli Valli Venkata SRIKANTH, Mohammed Naseer Ahmed KHAN, Mohammed Ashraf, Irum SEHAR,Gousia CHASHOO, Parduman Raj Sharma,Abid Hamid DAR, Bhushan SHASHI,Shashank Kumar Singh, Dilip Manikrao Mondhe, Ajit Kumar Saxena

“2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof”

US Patent no. US9029553 B2

(Granted : 2015)

Ghulam Nabi Qazi, Ajit Kumar Saxena,Shanmugavel Muthiah, Dilip Manikrao Mondhe, Parduman Raj Sharma, Shashank Kumar Singh, Utpal Sanyal, Asama Mukherjee, Suva Hazra, Susanta Dutta

Substituted 1H-benz[de]isoquinoline-1,3-diones.

EU Patent no. EP2118065 B1

(Granted :2013)

MSK Halmuthur, AK Saxena, SC Taneja, SK Singh, VK Sethi, NA Qazi

Spiro derivatives of parthenin as novel anticancer agents

US Patent 8,609,858 12013

(Granted :2011)

She is working on pharmacological aspects of cannabinoid receptor and their ligand in cancer therapeutics. Studying the regulation of the CB2 receptor pathway with its agonist/antagonist individually or in combination (combination with other cannabinoid or other pharmacological active compound which regulates the downstream proteins of cannabinoid pathway) for their anticancer potential and anticancer immunity.

Ms. Sheel Priya

She is working on potential application of endocannabinoid system (ECS) agents, acting as Anti-cancer entities, particularly, by activating Cannabinoid receptor 2(CB2R) in cancer cells, to prevent proliferation and metastasis in various cancers. Her main focus is, the activation of Cannabinoid receptor 2 (CB2R), its precise molecular mechanism and therapeutic potential assessment in cancer.

(UGC-JRF)

Ms. Kajal Thakur

She is working on potential application of endocannabinoid system (ECS) agents, acting as Anti-cancer entities, particularly, by activating Cannabinoid receptor 2(CB2R) in Breast cancer cells, to prevent invasion and metastasis in Breast cancer. Her main focus is, the activation of Cannabinoid receptor 2 (CB2R), its precise molecular mechanism and therapeutic potential assessment in Breast cancer.

(UGC-JRF)

Mr. Sahil Wassan

Currently engaged in research exploring the molecular mechanisms and therapeutic potential of CB2 and TRPV1 agonists in leukemia. The study focuses on evaluating the impact of CB2 and TRPV1 receptor activation on gene expression in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) cells, particularly in relation to apoptotic pathways, proliferation markers, and immune regulation. This work aims to uncover novel, targeted, and low-toxicity therapeutic strategies that could improve treatment outcomes and help overcome drug resistance in leukemia.

(DST-Inspire)

Mr. Vishal Kumar

His primary focus on head and neck squamous cell carcinoma (HNSCC). His work centers on unraveling the complexities of tumor immunology and the tumor microenvironment to design novel therapeutic approaches. Currently, he is investigating the synergistic potential of a thienopyrimidinyl-pyrazole-based PDE-5 inhibitor in combination with a PD-L1 inhibitor as an immunotherapeutic strategy against HNSCC.

(DST-Inspire)

Ms Shabu Thakur

Her interest includes the discovery and development of novel small-molecule inhibitors targeting key oncogenic signaling pathways. He is currently focused on a thieno[3,2-d]pyrimidinyl-based compound, specifically ((piperidin-4-yl)urea) derivatives, as potent, selective, and orally bioavailable inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK1). This research aims to evaluate their therapeutic potential in triple-negative breast cancer (TNBC), demonstrating significant in vitro and in vivo antitumor efficacy, with the goal of advancing targeted therapies for aggressive and treatment-resistant cancer subtypes.

(ICMR-JRF)

Dr. Gousia Chashoo

Her research includes the evaluation of PARP inhibitors as therapeutic agents for breast and ovarian cancers. She investigates their mechanisms of action and therapeutic potential, aiming to advance more effective and targeted treatment strategies. Her work bridges molecular biology, pharmacology, and translational cancer research to contribute to the development of precision oncology approaches.

DST-Women Scientist

Dr. Ajeet Singh

Working on the CSIR-PAN Cancer Mission Project focused on the development of a selective and orally bioavailable inhibitor of 3-phosphoinositide-dependent kinase-1 (PDK1). The project aims to evaluate its in vitro and in vivo antitumor efficacy in triple-negative breast cancer (TNBC), with the goal of advancing targeted therapeutic strategies for this aggressive cancer subtype

PA-1

Ms. Monica Sangral

She is currently working in the project HCP-40 entitled “Making Cancer Care Affordable: Empowering Women’s Health- Focussing on Breast and Gynaecological Cancers of Indian Relevance”. Her work is to acquire and analyse flow cytometry based experiments enabling to understand the effect of natural and synthetic compounds on cell apoptosis, cell cycle, drug uptake, cellular ROS generation etc.

PA-II

Dr. Sameer K. Varma

He is developing a clinical-grade dendritic cell-based immunotherapy for triple-negative breast cancer (TNBC)—a highly aggressive subtype that predominantly affects younger women and lacks effective targeted therapies. He is leading the innovation of a non-viral delivery system for precise antigen loading into dendritic cells. This strategy significantly enhances MHC-I and MHC-II expression, resulting in highly potent antigen-presenting cells capable of activating both cytotoxic and helper T cells. The outcome is a strong, specific immune response against TNBC. Together, we are building a safe, scalable, and translational immunotherapy platform, grounded in cutting-edge science and a steadfast commitment to patient-centered innovation.

Start-up Incubatee

Adoptive Biotech Pvt. Ltd. New Delhi